Time course of adverse events in the phase III GRID study of regorafenib in patients with metastatic gastrointestinal stromal tumors (GIST)

Author(s):
Bauer, S.; Blay, J.Y.; Casali, P.G.; Reichardt, P.; Kang, Y.K.; Rutkowski, P.; Gelderblom, H.; Hohenberger, P.; Kappeler, C.; Kuss, I.; Demetri, G.D.
Published
2013
Publication type
Article / Letter to editor
Date issued
2013-09-30
Language
English
Is part of
European Journal of Cancer (2013), Vol. 49, p. S884-S885
hdl
1887/100084